Markus Hartenfeller
Markus Hartenfeller
Unknown affiliation
Verified email at molecularhealth.com
Title
Cited by
Cited by
Year
DOGS: Reaction-Driven de novo Design of Bioactive Compounds
M Hartenfeller, H Zettl, M Walter, M Rupp, F Reisen, E Proschak, ...
PLoS Computational Biology 8 (2), e1002380, 2012
1342012
De novo drug design
M Hartenfeller, G Schneider
Methods Mol Biol 672, 299-323, 2011
1042011
Voyages to the (un) known: adaptive design of bioactive compounds
G Schneider, M Hartenfeller, M Reutlinger, Y Tanrikulu, E Proschak, ...
Trends in Biotechnology 27 (1), 18-26, 2009
892009
A Collection of Robust Organic Synthesis Reactions for In Silico Molecule Design
M Hartenfeller, M Eberle, P Meier, C Nieto-Oberhuber, KH Altmann, ...
Journal of chemical information and modeling 51 (12), 3093-3098, 2011
702011
Concept of Combinatorial De Novo Design of Drug‐like Molecules by Particle Swarm Optimization
M Hartenfeller, E Proschak, A Schüller, G Schneider
Chemical Biology & Drug Design 72 (1), 16-26, 2008
612008
Enabling future drug discovery by de novo design
M Hartenfeller, G Schneider
Wiley Interdisciplinary Reviews: Computational Molecular Science 1 (5), 742-759, 2011
582011
Probing the Bioactivity-Relevant Chemical Space of Robust Reactions and Common Molecular Building Blocks
M Hartenfeller, M Eberle, P Meier, C Nieto-Oberhuber, KH Altmann, ...
Journal of chemical information and modeling 52 (5), 1167-1178, 2012
382012
Reaction-driven de novo design, synthesis and testing of potential type II kinase inhibitors
G Schneider, T Geppert, M Hartenfeller, F Reisen, A Klenner, ...
Future medicinal chemistry 3 (4), 415-424, 2011
312011
Drugs by Numbers: Reaction‐Driven De Novo Design of Potent and Selective Anticancer Leads
B Spänkuch, S Keppner, L Lange, T Rodrigues, H Zettl, CP Koch, ...
Angewandte Chemie International Edition 52 (17), 4676-4681, 2013
292013
Concepts and Applications of Natural Computing Techniques in De Novo Drug and Peptide Design
J A Hiss, M Hartenfeller, G Schneider
Current Pharmaceutical Design 16 (15), 1656-1665, 2010
292010
‘Fuzziness’ in pharmacophore-based virtual screening and de novo design
A Klenner, M Hartenfeller, P Schneider, G Schneider
Drug Discovery Today: Technologies 7 (4), e237-e244, 2010
212010
Multistep Virtual Screening for Rapid and Efficient Identification of Non‐Nucleoside Bacterial Thymidine Kinase Inhibitors
J Zander, M Hartenfeller, V Hähnke, E Proschak, S Besier, TA Wichelhaus, ...
Chemistry-A European Journal 16 (31), 9630-9637, 2010
112010
Repurposing de novo designed entities reveals phosphodiesterase 3B and cathepsin L modulators
T Rodrigues, YC Lin, M Hartenfeller, S Renner, YF Lim, G Schneider
Chemical Communications 51 (35), 7478-7481, 2015
92015
Wirkstoffe nach Zahlen: reaktionsbasierter De‐novo‐Entwurf von potenten und selektiven Leitstrukturen für die Krebsforschung
B Spänkuch, S Keppner, L Lange, T Rodrigues, H Zettl, CP Koch, ...
Angewandte Chemie 125 (17), 4774-4779, 2013
52013
Development of a computational method for reaction-driven de novo design of druglike compounds
M Hartenfeller
Goethe University, Frankfurt am Main Google Scholar, 2010
42010
De novo Drug Design
G Schneider, M Hartenfeller, E Proschak
Lead Generation Approaches in Drug Discovery, 165-185, 2010
22010
Reaction‐Driven De Novo Design: a Keystone for Automated Design of Target Family‐Oriented Libraries
M Hartenfeller, S Renner, E Jacoby
De novo Molecular Design, 245-266, 2014
12014
P1-287 Confident BRCA1/2 variant classification: using ACMG and public data for systematic molecular profiling
U Schmidt-Edelkraut, E Ioana Braicu, S Kaduthanam, S Santiago-Mozos, ...
Annals of Oncology 29 (suppl_7), mdy375. 025, 2018
2018
Abstract A1-33: Knowledge prioritization of cancer genomes using oncoscores and functional impact scores to support biomarker discovery and clinical decision making
TG Soldatos, S Badbanchi, S Vivas, A Zien, F Diella, M Hartenfeller, ...
Cancer Research 75 (22 Supplement 1), A1-33-A1-33, 2015
2015
Identification of ERBB2 gene variants in HER2 positive disease associated with trastuzumab response in an adjuvant trastuzumab chemotherapy trial
S Gunn, A Zien, M Hartenfeller, F Diella, S Brock, M Stein, S Badbanchi, ...
CANCER RESEARCH 75 (9), 2015
2015
The system can't perform the operation now. Try again later.
Articles 1–20